Merck & Co., Inc. (NYSE:MRK) Shares Bought by ESG Planning

ESG Planning grew its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 27.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,769 shares of the company’s stock after buying an additional 805 shares during the period. Merck & Co., Inc. makes up approximately 0.4% of ESG Planning’s holdings, making the stock its 10th biggest position. ESG Planning’s holdings in Merck & Co., Inc. were worth $388,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRK. Telos Capital Management Inc. increased its stake in shares of Merck & Co., Inc. by 7.7% in the third quarter. Telos Capital Management Inc. now owns 13,774 shares of the company’s stock worth $1,418,000 after purchasing an additional 985 shares during the period. Axim Planning & Wealth bought a new position in Merck & Co., Inc. during the third quarter valued at about $226,000. Confluence Wealth Services Inc. increased its stake in Merck & Co., Inc. by 1.5% during the third quarter. Confluence Wealth Services Inc. now owns 34,176 shares of the company’s stock valued at $3,518,000 after acquiring an additional 502 shares during the period. Daiwa Securities Group Inc. increased its stake in Merck & Co., Inc. by 7.8% during the third quarter. Daiwa Securities Group Inc. now owns 303,521 shares of the company’s stock valued at $31,247,000 after acquiring an additional 21,875 shares during the period. Finally, Beaumont Financial Advisors LLC increased its stake in Merck & Co., Inc. by 2.6% during the third quarter. Beaumont Financial Advisors LLC now owns 22,433 shares of the company’s stock valued at $2,309,000 after acquiring an additional 558 shares during the period. Institutional investors and hedge funds own 74.59% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MRK. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Tuesday, January 9th. StockNews.com began coverage on Merck & Co., Inc. in a report on Thursday, October 5th. They set a “buy” rating on the stock. TheStreet raised Merck & Co., Inc. from a “c+” rating to a “b” rating in a report on Monday, November 27th. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and set a $132.00 price objective on the stock in a report on Friday, October 27th. Finally, UBS Group raised Merck & Co., Inc. from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $117.00 to $122.00 in a report on Friday, October 20th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $125.65.

Get Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Up 0.0 %

NYSE:MRK opened at $118.15 on Thursday. The stock’s fifty day moving average price is $107.51 and its two-hundred day moving average price is $106.87. Merck & Co., Inc. has a 52-week low of $96.36 and a 52-week high of $119.94. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.12 and a current ratio of 1.38. The company has a market cap of $299.39 billion, a price-to-earnings ratio of 65.63, a P/E/G ratio of 1.62 and a beta of 0.35.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, October 26th. The company reported $2.13 EPS for the quarter, beating the consensus estimate of $1.94 by $0.19. The company had revenue of $16 billion during the quarter, compared to analysts’ expectations of $15.30 billion. Merck & Co., Inc. had a net margin of 7.77% and a return on equity of 18.26%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.85 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 1.38 EPS for the current year.

Merck & Co., Inc. Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, January 8th. Shareholders of record on Friday, December 15th were given a dividend of $0.77 per share. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.73. The ex-dividend date was Thursday, December 14th. This represents a $3.08 annualized dividend and a dividend yield of 2.61%. Merck & Co., Inc.’s payout ratio is presently 171.11%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 43,823 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a total transaction of $4,602,729.69. Following the completion of the sale, the executive vice president now owns 111,764 shares in the company, valued at approximately $11,738,572.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 43,823 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a total transaction of $4,602,729.69. Following the completion of the sale, the executive vice president now owns 111,764 shares in the company, valued at approximately $11,738,572.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johannes Jacobus Oosthuizen sold 2,081 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $102.38, for a total transaction of $213,052.78. Following the completion of the sale, the insider now owns 18,191 shares of the company’s stock, valued at approximately $1,862,394.58. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.